Please login to the form below
oral myeloma therapy
This page shows the latest oral myeloma therapy news and features for those working in and with pharma, biotech and healthcare.
Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
adult patients with relapsed or refractory multiple myeloma (RRMM) who have received two or three lines of therapy, the company announced. ... This latest decision from NICE means that patients will now have routine access to the all-oral triplet therapy.
Latest news
-
Takeda can't sway NICE on oral myeloma therapy Ninlaro
Drug not recommended for NHS use in England and Wales. NICE has stuck to its decision not to recommend Takeda's multiple myeloma therapy Ninlaro for routine use in the NHS ... standard in myeloma treatment and patients in the UK deserve to have access to
-
Novel therapies for blood cancers showcased at ASH
Meanwhile, CAR-T therapy has also been shown for the first time at this year's ASH to have a therapeutic benefit in multiple myeloma. ... cancer. There was also encouraging new data for Takeda's multiple myeloma therapy Ninlaro (ixazomib; MLN9708), which
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
